Quarterly report pursuant to Section 13 or 15(d)

SHARE-BASED COMPENSATION (Tables)

v3.23.3
SHARE-BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of summarizes share-based compensation expense
                               
    Three Months Ended
September 30,
   

Nine Months Ended

September 30,

 
    2023     2022     2023     2022  
Research and development   $ 354     $ 1,007     $ 1,455     $ 3,142  
Sales and marketing     777       945       1,801       3,225  
General and administrative     970       3,835       2,768       12,850  
Cost of sales     6       76       20       182  
Total share-based compensation   $ 2,107     $ 5,863     $ 6,044     $ 19,399  
Schedule of common stock options
                               
    Number of
Shares
    Weighted
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
Life (Years)
    Weighted-
Average
Grant Date
Fair Value
 
Outstanding, December 31, 2022     7,812,178     $ 3.70       6.56     $ 2.23  
Granted     15,000       0.14       -       -  
Forfeited     (352,739 )     2.64       -       1.52  
Expired     (139,404 )     2.81       -       1.55  
Outstanding, September 30, 2023(a)     7,335,035     $ 3.76       4.86     $ 2.00  
Exercisable, September 30, 2023(b)     5,681,575     $ 3.91       4.03     $ 2.07  

 

 
(a) There was no aggregate intrinsic value of all stock options outstanding as of September 30, 2023.
(b) There was no aggregate intrinsic value of all vested/exercisable stock options as of September 30, 2023.
Schedule of unvested restricted stock units
               
    Number of
RSUs
    Weighted
Average
Grant Date
Fair Value
 
Outstanding (nonvested), December 31, 2022     4,267,746     $ 3.58  
Granted     681,620       0.56  
Released     (443,105 )     5.27  
Forfeited     (446,392 )     3.32  
Outstanding (nonvested), September 30, 2023     4,059,869     $ 2.92